Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis.

Igarashi A, Hunt B, Wilkinson L, Langer J, Pollock RF

Advances in therapy1 Sept 2020Cited by 8 (Europe PMC)

PMID32870471DOI10.1007/s12325-020-01476-xPepBankPUB-32870471

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study12

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone12

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01Computer modelNot a test of Semaglutide aloneIn silicoOther
In a Japanese economic analysis of diabetes treatment, semaglutide had lower drug costs than dulaglutide.
In plain wordsIn a Japanese economic model of diabetes treatment, semaglutide cost less than dulaglutide.
Peptide
Semaglutide
Outcome
DecreaseTreatment cost
Study
n: not reported in source
Comparator
Dulaglutide 0.75 mg
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Treatment with once-weekly semaglutide 0.5 mg was associated with a lower cost and a lower cost per patient treated to target for all endpoints, compared with once-weekly dulaglutide 0.75 mg.
3 context sentences(design, population, supporting numbers)
Summary · context
The objective of this analysis was to assess the short-term cost-effectiveness in Japan of once-weekly semaglutide 0.5 mg (the approved maintenance dose in Japan) compared with once-weekly dulaglutide 0.75 mg (the only licensed dose in Japan) over a 1-year period using Japanese cost data.
Summary · context
Responder endpoints were obtained from the SUSTAIN 7 trial to assess the cost of successfully treating patients to these targets ("cost of control").
Summary · context
The cost of treatment was accounted from a healthcare payer perspective, capturing drug costs only.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3287047101
02Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a Japanese economic analysis of diabetes treatment, dulaglutide had higher drug costs than semaglutide.
In plain wordsIn a Japanese economic model of diabetes treatment, dulaglutide cost more than semaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseTreatment cost
Study
n: not reported in source
Comparator
Semaglutide 0.5 mg
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Treatment with once-weekly semaglutide 0.5 mg was associated with a lower cost and a lower cost per patient treated to target for all endpoints, compared with once-weekly dulaglutide 0.75 mg.
3 context sentences(design, population, supporting numbers)
Summary · context
The objective of this analysis was to assess the short-term cost-effectiveness in Japan of once-weekly semaglutide 0.5 mg (the approved maintenance dose in Japan) compared with once-weekly dulaglutide 0.75 mg (the only licensed dose in Japan) over a 1-year period using Japanese cost data.
Summary · context
Responder endpoints were obtained from the SUSTAIN 7 trial to assess the cost of successfully treating patients to these targets ("cost of control").
Summary · context
The cost of treatment was accounted from a healthcare payer perspective, capturing drug costs only.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3287047102
03Computer modelNot a test of Semaglutide aloneIn silicoOther
In a Japanese diabetes model, semaglutide had lower cost per target achieved for the stricter HbA1c target than dulaglutide.
In plain wordsIn a Japanese diabetes model, semaglutide cost less than dulaglutide per target achieved for the stricter blood sugar target.
Peptide
Semaglutide
Outcome
DecreaseCost of HbA1c ≤6.5% target
Study
n: not reported in source
Comparator
Dulaglutide 0.75 mg
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Treatment with once-weekly semaglutide 0.5 mg was associated with a lower cost and a lower cost per patient treated to target for all endpoints, compared with once-weekly dulaglutide 0.75 mg.
5 context sentences(design, population, supporting numbers)
Summary · context
For each JPY 1 spent on bringing patients to target with once-weekly semaglutide 0.5 mg, JPY 1.58, JPY 1.44, JPY 1.60, JPY 2.10, and JPY 2.33 would need to be spent on once-weekly dulaglutide 0.75 mg to achieve an equivalent outcome
Summary · context
for endpoints of HbA1c ≤ 6.5%, HbA1c < 7.0%, HbA1c < 7.0% without hypoglycemia, and no weight gain, weight loss ≥ 5%, and ≥ 1.0% HbA1c reduction and ≥ 3.0% weight loss, respectively.
Summary · context
The objective of this analysis was to assess the short-term cost-effectiveness in Japan of once-weekly semaglutide 0.5 mg (the approved maintenance dose in Japan) compared with once-weekly dulaglutide 0.75 mg (the only licensed dose in Japan) over a 1-year period using Japanese cost data.
Summary · context
Responder endpoints were obtained from the SUSTAIN 7 trial to assess the cost of successfully treating patients to these targets ("cost of control").
Summary · context
The cost of treatment was accounted from a healthcare payer perspective, capturing drug costs only.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3287047103
04Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a Japanese diabetes model, dulaglutide had higher cost per target achieved for the stricter HbA1c target than semaglutide.
In plain wordsIn a Japanese diabetes model, dulaglutide cost more than semaglutide per target achieved for the stricter blood sugar target.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseCost of HbA1c ≤6.5% target
Study
n: not reported in source
Comparator
Semaglutide 0.5 mg
Outcome group
Cost-effectiveness · Whole body
Measurements
Dulaglutide expenditure per JPY 1 semaglutide
1.58 JPY
HbA1c ≤6.5%
Source sentences
Summary
For each JPY 1 spent on bringing patients to target with once-weekly semaglutide 0.5 mg, JPY 1.58, JPY 1.44, JPY 1.60, JPY 2.10, and JPY 2.33 would need to be spent on once-weekly dulaglutide 0.75 mg to achieve an equivalent outcome
4 context sentences(design, population, supporting numbers)
Summary · context
for endpoints of HbA1c ≤ 6.5%, HbA1c < 7.0%, HbA1c < 7.0% without hypoglycemia, and no weight gain, weight loss ≥ 5%, and ≥ 1.0% HbA1c reduction and ≥ 3.0% weight loss, respectively.
Summary · context
The objective of this analysis was to assess the short-term cost-effectiveness in Japan of once-weekly semaglutide 0.5 mg (the approved maintenance dose in Japan) compared with once-weekly dulaglutide 0.75 mg (the only licensed dose in Japan) over a 1-year period using Japanese cost data.
Summary · context
Responder endpoints were obtained from the SUSTAIN 7 trial to assess the cost of successfully treating patients to these targets ("cost of control").
Summary · context
The cost of treatment was accounted from a healthcare payer perspective, capturing drug costs only.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3287047104
05Computer modelNot a test of Semaglutide aloneIn silicoOther
In a Japanese diabetes model, semaglutide had lower cost per target achieved for the HbA1c target than dulaglutide.
In plain wordsIn a Japanese diabetes model, semaglutide cost less than dulaglutide per target achieved for the blood sugar target.
Peptide
Semaglutide
Outcome
DecreaseCost of HbA1c <7.0% target
Study
n: not reported in source
Comparator
Dulaglutide 0.75 mg
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Treatment with once-weekly semaglutide 0.5 mg was associated with a lower cost and a lower cost per patient treated to target for all endpoints, compared with once-weekly dulaglutide 0.75 mg.
4 context sentences(design, population, supporting numbers)
Summary · context
for endpoints of HbA1c ≤ 6.5%, HbA1c < 7.0%, HbA1c < 7.0% without hypoglycemia, and no weight gain, weight loss ≥ 5%, and ≥ 1.0% HbA1c reduction and ≥ 3.0% weight loss, respectively.
Summary · context
The objective of this analysis was to assess the short-term cost-effectiveness in Japan of once-weekly semaglutide 0.5 mg (the approved maintenance dose in Japan) compared with once-weekly dulaglutide 0.75 mg (the only licensed dose in Japan) over a 1-year period using Japanese cost data.
Summary · context
Responder endpoints were obtained from the SUSTAIN 7 trial to assess the cost of successfully treating patients to these targets ("cost of control").
Summary · context
The cost of treatment was accounted from a healthcare payer perspective, capturing drug costs only.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3287047105
06Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a Japanese diabetes model, dulaglutide had higher cost per target achieved for the HbA1c target than semaglutide.
In plain wordsIn a Japanese diabetes model, dulaglutide cost more than semaglutide per target achieved for the blood sugar target.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseCost of HbA1c <7.0% target
Study
n: not reported in source
Comparator
Semaglutide 0.5 mg
Outcome group
Cost-effectiveness · Whole body
Measurements
Dulaglutide expenditure per JPY 1 semaglutide
1.44 JPY
HbA1c <7.0%
Source sentences
Summary
For each JPY 1 spent on bringing patients to target with once-weekly semaglutide 0.5 mg, JPY 1.58, JPY 1.44, JPY 1.60, JPY 2.10, and JPY 2.33 would need to be spent on once-weekly dulaglutide 0.75 mg to achieve an equivalent outcome
4 context sentences(design, population, supporting numbers)
Summary · context
for endpoints of HbA1c ≤ 6.5%, HbA1c < 7.0%, HbA1c < 7.0% without hypoglycemia, and no weight gain, weight loss ≥ 5%, and ≥ 1.0% HbA1c reduction and ≥ 3.0% weight loss, respectively.
Summary · context
The objective of this analysis was to assess the short-term cost-effectiveness in Japan of once-weekly semaglutide 0.5 mg (the approved maintenance dose in Japan) compared with once-weekly dulaglutide 0.75 mg (the only licensed dose in Japan) over a 1-year period using Japanese cost data.
Summary · context
Responder endpoints were obtained from the SUSTAIN 7 trial to assess the cost of successfully treating patients to these targets ("cost of control").
Summary · context
The cost of treatment was accounted from a healthcare payer perspective, capturing drug costs only.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3287047106
07Computer modelNot a test of Semaglutide aloneIn silicoOther
In a Japanese diabetes model, semaglutide cost less than dulaglutide per target achieved for the combined glycemic and safety target.
In plain wordsIn a Japanese diabetes model, semaglutide cost less than dulaglutide per target achieved for the combined blood sugar and safety target.
Peptide
Semaglutide
Outcome
DecreaseCost of HbA1c target without hypoglycemia or weight gain
Study
n: not reported in source
Comparator
Dulaglutide 0.75 mg
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Treatment with once-weekly semaglutide 0.5 mg was associated with a lower cost and a lower cost per patient treated to target for all endpoints, compared with once-weekly dulaglutide 0.75 mg.
4 context sentences(design, population, supporting numbers)
Summary · context
for endpoints of HbA1c ≤ 6.5%, HbA1c < 7.0%, HbA1c < 7.0% without hypoglycemia, and no weight gain, weight loss ≥ 5%, and ≥ 1.0% HbA1c reduction and ≥ 3.0% weight loss, respectively.
Summary · context
The objective of this analysis was to assess the short-term cost-effectiveness in Japan of once-weekly semaglutide 0.5 mg (the approved maintenance dose in Japan) compared with once-weekly dulaglutide 0.75 mg (the only licensed dose in Japan) over a 1-year period using Japanese cost data.
Summary · context
Responder endpoints were obtained from the SUSTAIN 7 trial to assess the cost of successfully treating patients to these targets ("cost of control").
Summary · context
The cost of treatment was accounted from a healthcare payer perspective, capturing drug costs only.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3287047107
08Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a Japanese diabetes model, dulaglutide cost more than semaglutide per target achieved for the combined glycemic and safety target.
In plain wordsIn a Japanese diabetes model, dulaglutide cost more than semaglutide per target achieved for the combined blood sugar and safety target.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseCost of HbA1c target without hypoglycemia or weight gain
Study
n: not reported in source
Comparator
Semaglutide 0.5 mg
Outcome group
Cost-effectiveness · Whole body
Measurements
Dulaglutide expenditure per JPY 1 semaglutide
1.6 JPY
HbA1c <7.0% without hypoglycemia and no weight gain
Source sentences
Summary
For each JPY 1 spent on bringing patients to target with once-weekly semaglutide 0.5 mg, JPY 1.58, JPY 1.44, JPY 1.60, JPY 2.10, and JPY 2.33 would need to be spent on once-weekly dulaglutide 0.75 mg to achieve an equivalent outcome
4 context sentences(design, population, supporting numbers)
Summary · context
for endpoints of HbA1c ≤ 6.5%, HbA1c < 7.0%, HbA1c < 7.0% without hypoglycemia, and no weight gain, weight loss ≥ 5%, and ≥ 1.0% HbA1c reduction and ≥ 3.0% weight loss, respectively.
Summary · context
The objective of this analysis was to assess the short-term cost-effectiveness in Japan of once-weekly semaglutide 0.5 mg (the approved maintenance dose in Japan) compared with once-weekly dulaglutide 0.75 mg (the only licensed dose in Japan) over a 1-year period using Japanese cost data.
Summary · context
Responder endpoints were obtained from the SUSTAIN 7 trial to assess the cost of successfully treating patients to these targets ("cost of control").
Summary · context
The cost of treatment was accounted from a healthcare payer perspective, capturing drug costs only.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3287047108
09Computer modelNot a test of Semaglutide aloneIn silicoOther
In a Japanese diabetes model, semaglutide cost less than dulaglutide per target achieved for the weight loss target.
In plain wordsIn a Japanese diabetes model, semaglutide cost less than dulaglutide per target achieved for the weight loss target.
Peptide
Semaglutide
Outcome
DecreaseCost of weight loss target
Study
n: not reported in source
Comparator
Dulaglutide 0.75 mg
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Treatment with once-weekly semaglutide 0.5 mg was associated with a lower cost and a lower cost per patient treated to target for all endpoints, compared with once-weekly dulaglutide 0.75 mg.
4 context sentences(design, population, supporting numbers)
Summary · context
for endpoints of HbA1c ≤ 6.5%, HbA1c < 7.0%, HbA1c < 7.0% without hypoglycemia, and no weight gain, weight loss ≥ 5%, and ≥ 1.0% HbA1c reduction and ≥ 3.0% weight loss, respectively.
Summary · context
The objective of this analysis was to assess the short-term cost-effectiveness in Japan of once-weekly semaglutide 0.5 mg (the approved maintenance dose in Japan) compared with once-weekly dulaglutide 0.75 mg (the only licensed dose in Japan) over a 1-year period using Japanese cost data.
Summary · context
Responder endpoints were obtained from the SUSTAIN 7 trial to assess the cost of successfully treating patients to these targets ("cost of control").
Summary · context
The cost of treatment was accounted from a healthcare payer perspective, capturing drug costs only.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3287047109
10Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a Japanese diabetes model, dulaglutide cost more than semaglutide per target achieved for the weight loss target.
In plain wordsIn a Japanese diabetes model, dulaglutide cost more than semaglutide per target achieved for the weight loss target.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseCost of weight loss target
Study
n: not reported in source
Comparator
Semaglutide 0.5 mg
Outcome group
Cost-effectiveness · Whole body
Measurements
Dulaglutide expenditure per JPY 1 semaglutide
2.1 JPY
weight loss ≥5%
Source sentences
Summary
For each JPY 1 spent on bringing patients to target with once-weekly semaglutide 0.5 mg, JPY 1.58, JPY 1.44, JPY 1.60, JPY 2.10, and JPY 2.33 would need to be spent on once-weekly dulaglutide 0.75 mg to achieve an equivalent outcome
4 context sentences(design, population, supporting numbers)
Summary · context
for endpoints of HbA1c ≤ 6.5%, HbA1c < 7.0%, HbA1c < 7.0% without hypoglycemia, and no weight gain, weight loss ≥ 5%, and ≥ 1.0% HbA1c reduction and ≥ 3.0% weight loss, respectively.
Summary · context
The objective of this analysis was to assess the short-term cost-effectiveness in Japan of once-weekly semaglutide 0.5 mg (the approved maintenance dose in Japan) compared with once-weekly dulaglutide 0.75 mg (the only licensed dose in Japan) over a 1-year period using Japanese cost data.
Summary · context
Responder endpoints were obtained from the SUSTAIN 7 trial to assess the cost of successfully treating patients to these targets ("cost of control").
Summary · context
The cost of treatment was accounted from a healthcare payer perspective, capturing drug costs only.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3287047110
11Computer modelNot a test of Semaglutide aloneIn silicoOther
In a Japanese diabetes model, semaglutide cost less than dulaglutide per target achieved for combined HbA1c reduction and weight loss targets.
In plain wordsIn a Japanese diabetes model, semaglutide cost less than dulaglutide per target achieved for combined blood sugar reduction and weight loss targets.
Peptide
Semaglutide
Outcome
DecreaseCost of combined HbA1c reduction and weight loss target
Study
n: not reported in source
Comparator
Dulaglutide 0.75 mg
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Treatment with once-weekly semaglutide 0.5 mg was associated with a lower cost and a lower cost per patient treated to target for all endpoints, compared with once-weekly dulaglutide 0.75 mg.
4 context sentences(design, population, supporting numbers)
Summary · context
for endpoints of HbA1c ≤ 6.5%, HbA1c < 7.0%, HbA1c < 7.0% without hypoglycemia, and no weight gain, weight loss ≥ 5%, and ≥ 1.0% HbA1c reduction and ≥ 3.0% weight loss, respectively.
Summary · context
The objective of this analysis was to assess the short-term cost-effectiveness in Japan of once-weekly semaglutide 0.5 mg (the approved maintenance dose in Japan) compared with once-weekly dulaglutide 0.75 mg (the only licensed dose in Japan) over a 1-year period using Japanese cost data.
Summary · context
Responder endpoints were obtained from the SUSTAIN 7 trial to assess the cost of successfully treating patients to these targets ("cost of control").
Summary · context
The cost of treatment was accounted from a healthcare payer perspective, capturing drug costs only.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3287047111
12Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a Japanese diabetes model, dulaglutide cost more than semaglutide per target achieved for combined HbA1c reduction and weight loss targets.
In plain wordsIn a Japanese diabetes model, dulaglutide cost more than semaglutide per target achieved for combined blood sugar reduction and weight loss targets.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseCost of combined HbA1c reduction and weight loss target
Study
n: not reported in source
Comparator
Semaglutide 0.5 mg
Outcome group
Cost-effectiveness · Whole body
Measurements
Dulaglutide expenditure per JPY 1 semaglutide
2.33 JPY
HbA1c reduction ≥1.0% and weight loss ≥3.0%
Source sentences
Summary
For each JPY 1 spent on bringing patients to target with once-weekly semaglutide 0.5 mg, JPY 1.58, JPY 1.44, JPY 1.60, JPY 2.10, and JPY 2.33 would need to be spent on once-weekly dulaglutide 0.75 mg to achieve an equivalent outcome
4 context sentences(design, population, supporting numbers)
Summary · context
for endpoints of HbA1c ≤ 6.5%, HbA1c < 7.0%, HbA1c < 7.0% without hypoglycemia, and no weight gain, weight loss ≥ 5%, and ≥ 1.0% HbA1c reduction and ≥ 3.0% weight loss, respectively.
Summary · context
The objective of this analysis was to assess the short-term cost-effectiveness in Japan of once-weekly semaglutide 0.5 mg (the approved maintenance dose in Japan) compared with once-weekly dulaglutide 0.75 mg (the only licensed dose in Japan) over a 1-year period using Japanese cost data.
Summary · context
Responder endpoints were obtained from the SUSTAIN 7 trial to assess the cost of successfully treating patients to these targets ("cost of control").
Summary · context
The cost of treatment was accounted from a healthcare payer perspective, capturing drug costs only.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3287047112

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 2
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.